Table 3.

Overview of pooled results of the prognostic value of hematologic parameters

	Outcome	No.	HR	95% CI	P	I-squared (%)	P H
NLR	OS	26	1.55	1.37–1.76	0.000	83.0	0.000
	CSS	4	1.14	0.89–1.45	0.297	61.5	0.050
	PFS	12	1.62	1.29–2.04	0.000	67.6	0.000
	DMFS	2	1.81	0.55–6.01	0.330	92.3	0.000
	RFS	6	1.12	1.04–1.20	0.002	0.0	0.560
PLR	OS	6	1.72	1.36–2.18	0.000	0.0	0.575
	CSS	3	1.56	0.82–2.97	1.000	78.7	0.009
PLT	OS	3	1.00	0.98–1.02	0.910	59.3	0.086
	CSS	4	1.00	0.99–1.01	0.850	15.4	0.315
LMR	OS	2	2.27	1.76–2.94	0.000	27.8	0.239
	PFS	2	2.18	1.58–3.02	0.000	0.0	0.460
Lymphocyte	OS	4	0.96	0.83–1.10	0.710	0.0	0.529
	CSS	3	0.85	0.66–1.09	0.190	0.0	0.523
	RFS	2	1.06	0.96–1.16	0.260	0.0	0.824
Neutrophil	OS	3	1.10	1.03–1.18	0.006	0.0	0.604
	CSS	2	1.12	0.99–1.25	0.065	0.0	0.771
	RFS	2	1.03	0.98–1.09	0.188	0.0	0.421
Monocyte	OS	3	2.25	1.67–3.05	0.000	1.54	0.463
	PFS	3	1.75	1.36–2.25	0.000	33.2	0.224

OS, overall survival; CSS, cancer-specific survival; PFS, progression-free survival; DMFS, distant metastases-free survival; RFS, recurrence-free survival; PLR, platelet to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; LMR, lymphocyte to monocyte ratio; PLT, platelet; HR, hazard ratio; CI, confidence intervals; P_H, heterogeneity of P-value